Animal Testing Market Definition
The animal testing market consists of the total expenses incurred by end-use entities that use animals for testing their products. End-use entities include academic research institutions and various industries (such as pharmaceuticals, medical devices, chemicals & pesticides and cosmetics,) that conduct animal testing during product development. Pharmaceutical and medical device companies also use animal testing to understand basic disease mechanisms. End-use entities may also outsource these tests to clinical research organizations (CROs). The animal testing market covered in this report includes sales of animal testing services by CROs to end use industries.
The market includes the costs of animal models and the costs of animal testing operations (such as animal maintenance and feed) during drug/ product testing. This market does not include animals caged in companies as stock and not used for testing, and animals used for breeding.
Non-Animal Alternative Testing Market Definition
The non-animal alternative testing market is the total expenses incurred by end-use entities that use alternative technologies instead of animals for testing their products. End-use entities include academic research institutions, and various industries (such as pharmaceuticals, medical devices, chemicals & pesticides and cosmetics) performing animal testing to conduct basic research, toxicology profiling, and others. The non-animal testing market covered in this report includes sales of non-animal testing services by CROs to end use industries.
The market is inclusive of the costs of alternate technology tools and other operational costs involved in using these tools for various preclinical testing purposes.
Animal Testing And Non-Animal Testing Market Size
The global animal testing market was valued at $10.74 billion in 2019and the market is expected to grow at a compound annual growth rate (CAGR) of 4.27% during 2019-2025 and at a CAGR of 2.46% during 2025-2035.
Growth in the forecast period will result from the need for preclinical studies for the approval of therapeutics, increasing investment in R&D by the pharmaceutical companies, advances in genetic engineering, and the need for animal models to understand the complexity of biologics.
The global non-animal alternative testing market was valued at $1.11 billion in 2019. The market is expected to grow at a CAGR of 10.40% during 2019-2025 and at a CAGR of 11.62% during 2025-2035.
Growth in the forecast period will result from increasing adoption of in-vitro and in-silico technologies in basic research by pharmaceutical industry, increasing adoption of non-animal testing technologies in preclinical research, government programs for non-animal alternative testing, ethical concerns on animal experimentations, high costs of animal studies, and increasing social awareness against animal cruelty.
Animal Testing Market Drivers
The key drivers of the animal testing market include:
The Need For Preclinical Studies For The Approval Of Therapeutics
The need for preclinical studies is on the rise as the researchers gain insights on new drug candidates’ dosing and toxicity while conducting these studies in animal models. Preclinical studies provide information about the safety and efficacy of a drug candidate before testing it in humans. The studies require appropriate preclinical models that are comparable to the target population to ensure reliable results. According to clinicalTrials.gov, a web-based resource which provides data on clinical studies, as of February 2020, there were 330,113 clinical studies registered, of which 34% were from the USA.
With the growing need for drug discovery and development, the need for animal models in preclinical studies is also growing.
Non-Animal Alternative Testing Market Drivers
The key drivers of the non-animal alternative testing market include:
Ethical Concerns On Animal Experimentations
Alternative animal testing technologies are increasingly adopted by the end-use industries due to the pressure from animal rights organizations such as PETA, and Cruelty-Free International to treat animals in an ethical way. These animal rights organizations are protesting and conducting media campaigns in order to stop animal physiological distress and suffering for research on drugs, cosmetic products, chemicals, and food ingredients. These organizations are working closely with government agencies, educational institutions, and end-use industries to provide funding for developing alternative technologies. Therefore, ethical concerns on animal experiments are creating new legislation in various countries thereby driving the alternative technologies market.
Animal Testing Market Restraints
The key restraints on the animal testing market include:
The High Cost Of Animal Studies
The high cost associated with animal testing is challenging the growth of this market. The total cost of animal use in research studies is the sum of the cost of acquisition of the animals and that of maintaining the animals prior to and during their use. The maintenance cost and the actual cost for a particular species vary with the sex, strain, weight, age, quantity ordered, method of shipping, and distance shipped. According to an animal supply company, New Zealand White Rabbits cost as high as $352 each, purebred Beagles for $1,049 and some primates costing more than $8,000 each. Additionally, there is human labor cost, as the animals need an attendant.
The high cost of animal studies is hindering the animal testing market, and in a way boosting the adoption of alternative testing methods.
Non-Animal Alternative Testing Market Restraints
The key restraints on the non-animal alternative testing market include:
Regulatory Mandate On Animal Testing For Drug/Medical Device Approval
Regulatory authorities mandate animal testing for drug/medical approval in the pharmaceutical industry. Regulatory bodies such as the US Food and Drug Administration (FDA) follow the Animal Efficacy Rule, a regulation to approve products for further clinical studies based on safety and efficacy studies in animals. The existence of animal testing regulation in the pharmaceutical industry is hindering the non-animal alternative testing market.
Non-Animal Alternative Testing Market Trends
Major trend influencing the non-animal alternative testing market include:
Increasing Collaborations & Partnerships To Reduce Animal Testing
End-use industries including cosmetics, pharmaceutical, medical devices, chemicals, and food companies are increasingly seeking partnerships and collaborations with the organizations involved in developing non-animal alternative testing technologies. Collaborations of these end-use companies with leading scientists, academic research institutions, government agencies, and non-profit organizations help them better understand the industry requirements and bottlenecks in the deployment of these alternative technologies.
For instance, Unilever has collaborated with the US Environmental Protection Agency (EPA) to develop alternatives to animal testing strategies. Since 2013, AstraZeneca has been collaborating with Emulate, Inc to develop organ-on-chip technology, which is expected to reduce the use of animals in research as well as the cost and time of discovery and development. In a similar way, the Estee Lauder Companies recently expanded its partnership with cruelty-free international and humane society international to end animal testing in cosmetics.
Companies involved in non-animal testing should consider collaborating with end users to understand the industry requirements and bottlenecks.
Opportunities And Recommendations In The Animal Testing And Non-Animal Alternative Testing Market
Opportunities – The animal testing market size will gain the most in the ROW at $1.590 billion in 2025 and $2.314 billion in 2035.
The non-animal alternative testing market size will gain the most in Europe at $0.469 billion in 2025 and $1.456 billion in 2035.Market-trend-based strategies for the non-animal alternative testing market include collaborating with end users to understand the industry requirements and bottlenecks, and focusing on developing testing methods for the cosmetics industry to capitalize on increasing demand from the cosmetics industry. Player-adopted strategies in the non-animal alternative testing market include developing strategic partnerships and collaborations to expand R&D operations.
Recommendations – To take advantage of these opportunities, The Business Research Company recommends the animal testing and non-animal alternative testing companies to focus on R&D to develop disease models , develop human-on-chip models, focus on pricing based on economies, focus on developing economies, use direct-to-consumer (DTC) advertising, collaborate with end user companies, and focus on people with specific diseases.
Animal Testing And Non-Animal Testing Market Segmentation
The animal testing market is segmented by type of end use industrial application, and by geography.
By End-Use -
The animal market can be segmented by end-use industrial application into
- a) Pharmaceuticals
- b) Academic Research
- c) Medical Devices
- d) Chemicals & Pesticides
- e) Cosmetics
- f) Others
By Geography - The animal testing market is segmented into
- o USA
- o Japan
- o China
- o Australia
- o France
- o Canada
- o UK
- o Germany
By Geography - The non-animal alternative testing market is segmented into
- o USA
- o Japan
- o Europe
- o ROW
Non-Animal Alternative Testing Competitive Landscape
Major Competitors are:
Other Competitors Include:
- • Emulate, Inc
- • Organovo Holdings, Inc
- • MatTek Corporation
- • EMD Millipore
- • China Tissue Engineering Co., Ltd. (J-TEC)
- • ReproCell Inc
- • Organ Technologies Co, Ltd
- • Episkin
- • Biochip
- • Hurel Corporation
- • Micronit
- • Tara Biosystems
- • BiomimX SRL
- • Elveflow
- • SynVivo
- • BeonChip
- • Mesobiotech
- • Cherry Biotech
- • 4DCell
- • uFluidix Inc.
- • CN Biosystems
- • Hurel Corporation
- • InSphero AG,
- • Nortis Inc.
- • HemoShear
- • Ascendance Bio
- • Organovo Holdings, Inc.